2Q EARNINGS: Aegerion beats consensus, raises Juxtapid guidance
This article was originally published in Scrip
Aegerion Pharmaceuticals beat Wall Street consensus for its first full quarter of Juxtapid (lomitapide) sales and raised its guidance for full-year 2013 revenue from the homozygous familial hypercholesterolemia (HoFH) drug.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.